Sustained remissions in CLL after frontline FCR treatment with very long-term follow-up

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) achieves durable remissions, with flattening of the progression-free survival (PFS) curve in patients with mutated IGHV gene (IGHV-M). We updated long-term follow-up results from the original 300 patient FCR study initiated at M.D. Anderson in 1999. Current median follow-up is 19.0 years. With this extended follow-up, the median PFS for patients with IGHV-M was 14.6 years vs 4.2 years for patients with unmutated …